首页|负载丹参酮ⅡA的磁性纳米粒子Fe3O4@ZIF-8 MOF制备、对骨髓间充质干细胞增殖和成骨分化促进作用观察

负载丹参酮ⅡA的磁性纳米粒子Fe3O4@ZIF-8 MOF制备、对骨髓间充质干细胞增殖和成骨分化促进作用观察

扫码查看
目的 制备负载丹参酮ⅡA的磁性纳米粒子Fe3O4@ZIF-8 MOF(Fe3O4@ZIF-8@Tan ⅡA),并观察Fe3O4@ZIF-8@Tan ⅡA对骨髓间充质干细胞(BMSCs)增殖、成骨分化的促进作用。方法 用沸石咪唑酯骨架材料(ZIF-8)对Fe3O4纳米粒进行表面修饰,将丹参酮ⅡA(Tan ⅡA)装载载入磁性纳米粒子Fe3O4@ZIF-8 MOF中,HPLC检测Fe3O4@ZIF-8@Tan ⅡA的载药量和包封率,测算Fe3O4@ZIF-8@Tan ⅡA的药物释放率。BMSCs细胞经体外培养后分为4组,对照组加入成骨诱导液+完全培养基,游离药物组加入成骨诱导液+含10。27 µg/mL的Tan ⅡA完全培养基,载体组加入成骨诱导液+含100 µg/mL的Fe3O4@ZIF-8 MOF完全培养基,载药组加入成骨诱导液+含100 µg/mL的Fe3O4@ZIF-8@Tan ⅡA完全培养基,采用MTT法检测各组不同时点(给药1、4、7 d)细胞OD值,碱性磷酸酶(ALP)试剂盒检测不同时点(给药1、4 d)ALP活性。结果 Fe3O4@ZIF-8@Tan ⅡA的平均粒径为307。12 nm,PDI为0。090,电位为-40。03 mV,呈类球形,表面较为粗糙,比表面积为337。32 m2/g,磁饱和强度约为48 emu/g,具有良好的超顺磁性;Fe3O4@ZIF-8@Tan ⅡA的载药量为10。27%,包封率为80。36%,体外释放具有pH响应性,能在骨质疏松微环境中加快释药速率。与对照组比较,载药组给药4 d细胞OD值增加,其余3组给药7 d细胞OD值增加(P均<0。05);与对照组比较,载药组给药1 d细胞ALP活性增强,载体组和载药组给药4 d细胞ALP活性增强(P均<0。05)。结论 Fe3O4@ZIF-8@Tan ⅡA具有良好的载药性能和超顺磁性,有较高的载药量和包封率,并能达到缓慢释放药物的效果,且能够改善Tan ⅡA水溶性、成药性差等缺点,Fe3O4@ZIF-8@Tan ⅡA对BMSCs的增殖和分化具有协同促进作用。
Preparation of magnetic nanoparticle Fe3O4@ZIF-8 MOF loaded with tanshinone ⅡA and its effects on proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells
Objective To prepare the magnetic nanoparticle Fe3O4@ZIF-8 MOF(Fe3O4@ZIF-8@Tan ⅡA)loaded with tanshinone ⅡA,and to observe the promoting effects of Fe3O4@ZIF-8@Tan ⅡA on proliferation and osteogenic differ-entiation of bone marrow mesenchymal stem cells(BMSCs).Methods Fe3O4 nanoparticles were surface-modified with zeolite imidazolate skeleton material(ZIF-8),and tanshinone ⅡA(Tan ⅡA)was loaded into magnetic nanoparticle Fe3O4@ZIF-8 MOF and the drug loading and encapsulation rate of Fe3O4@ZIF-8@Tan ⅡA were detected by HPLC,and the drug release rate of Fe3O4@ZIF-8@Tan ⅡA was calculated.BMSCs were divided into four groups after culture in vitro.BMSCs in the control group were added with osteogenic induction solution+complete medium;BMSCs in the free drug group were added with osteogenic induction solution+Tan ⅡA complete medium containing 10.27 µg/mL;BMSCs in the carrier group were added with osteogenic induction solution+Fe3O4@ZIF-8 MOF complete medium containing 100 µg/mL;in the drug loading group,osteogenic induction solution+Fe3O4@ZIF-8@Tan ⅡA complete medium containing 100 µg/mL were added.OD values of cells in each group were detected by MTT method at different time points(1,4,7 d),and ALP activity was detected by alkaline phosphatase(ALP)kit at different time points(1,4 d).Results The average particle size of Fe3O4@ZIF-8@Tan ⅡA was 307.12 nm,the PDI was 0.090,the potential was-40.03 mV;it was almost spherical with rough surface,the specific surface area was 337.32m2/g,the magnetic saturation intensity was about 48 emu/g,and it had good superparamagnetism.The drug loading capacity of Fe3O4@ZIF-8@Tan ⅡA was 10.27%,and the encapsula-tion efficiency was 80.36%.The in vitro release behavior of Fe3O4@ZIF-8@Tan ⅡA was pH-responsive and could acceler-ate the release rate in a stimulated osteoporotic microenvironment.Compared with the control group,OD value of cells in the loading group increased after four days of administration,and OD value of cells in the other three groups increased after 7 days of administration(all P<0.05).Compared with the control group,the ALP activity of cells in the drug loading group was enhanced after 1 day of administration,and the ALP activity of cells in the carrier group and the drug loading group was enhanced after 4 days of administration(all P<0.05).Conclusions Fe3O4@ZIF-8@Tan ⅡA has good drug loading performance,superparamagnetism,high drug loading capacity and encapsulation rate,and can achieve the effect of slow drug release,and improve the shortcomings of Tan ⅡA such as water solubility and poor drug formation.Fe3O4@ZIF-8@Tan ⅡA can synergistically promote the proliferation and differentiation of BMSCs.

tanshinone ⅡAmagnetic nanoparticlesMOFbone mesenchymal stem cellsosteoporosis

蒙泽婧、龙海军、陈滕、汪祖华、朱月

展开 >

贵州中医药大学药学院,贵阳 550025

贵州中医药大学纳米药物研究中心

丹参酮ⅡA 磁性纳米粒子 沸石咪唑酯骨架材料 骨髓间充质干细胞 骨质疏松

国家自然科学基金资助项目贵州省科技厅基础研究计划项目贵州省教育厅青年科技人才成长项目

32160227黔科合基础-ZK[2022]一般513黔教合KY字[2022]252号

2024

山东医药
山东卫生报刊社

山东医药

CSTPCD
影响因子:1.225
ISSN:1002-266X
年,卷(期):2024.64(24)